Oguzhan Ozturk

Dr. Oguzhan Ozturk


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2010 in Gastrointestinal Endoscopy
Verified
Journal Article
Open access
PDF file
ITIlyas Tuncer
Ilyas Tuncer
HDHamdi Levent Doganay
Hamdi Levent Doganay
OOOguzhan Ozturk
Oguzhan Ozturk

1 December 2016 in Proteome Science
Verified
Journal Article
Open access
PDF file
SKSeyma Katrinli
Seyma Katrinli
KOKamil Ozdil
Kamil Ozdil
ASAbdurrahman Sahin
Abdurrahman Sahin
OOOguzhan Ozturk
Oguzhan Ozturk
GKGozde Kir
Gozde Kir
GDGizem Dinler Doganay
Gizem Dinler Doganay
Hepatitis B virus (HBV) is a global health problem, and infected patients if left untreated may develop cirrhosis and eventually hepatocellular carcinoma. This study aims to enlighten pathways associated with HBV related liver fibrosis for delineation of potential new therapeutic targets and biomarkers. Tissue samples from 47 HBV infected patients with different fibrotic stages (F1 to F6) were enrolled for 2D-DIGE proteomic screening. Differentially expressed proteins were identified by mass spectrometry and verified by western blotting. Functional proteomic associations were analyzed by EnrichNet application. Fibrotic stage variations were observed for apolipoprotein A1 (APOA1), pyruvate kinase PKM (KPYM), glyceraldehyde 3-phospahate dehydrogenase (GAPDH), glutamate dehydrogenase (DHE3), aldehyde dehydrogenase (ALDH2), alcohol dehydrogenase (ALDH1A1), transferrin (TRFE), peroxiredoxin 3 (PRDX3), phenazine biosynthesis-like domain-containing protein (PBLD), immuglobulin kappa chain C region (IGKC), annexin A4 (ANXA4), keratin 5 (KRT5). Enrichment analysis with Reactome and Kegg databases highlighted the possible involvement of platelet release, glycolysis and HDL mediated lipid transport pathways. Moreover, string analysis revealed that HIF-1α (Hypoxia-inducible factor 1-alpha), one of the interacting partners of HBx (Hepatitis B X protein), may play a role in the altered glycolytic response and oxidative stress observed in liver fibrosis. To our knowledge, this is the first protomic research that studies HBV infected fibrotic human liver tissues to investigate alterations in protein levels and affected pathways among different fibrotic stages. Observed changes in the glycolytic pathway caused by HBx presence and therefore its interactions with HIF-1α can be a target pathway for novel therapeutic purposes.

1 June 2017 in Arab Journal of Gastroenterology
Verified
Journal Article
Closed access
OOOguzhan Ozturk
Oguzhan Ozturk
HDHamdi Levent Doganay
Hamdi Levent Doganay
YCYasar Colak
Yasar Colak
FEFeruze Yilmaz Enc
Feruze Yilmaz Enc
CUCelal Ulasoglu
Celal Ulasoglu
ITIlyas Tuncer
Ilyas Tuncer

1 January 2015 in World Journal of Gastroenterology
Verified
Journal Article
Open access
OOOguzhan Ozturk
Oguzhan Ozturk
YCYasar Colak
Yasar Colak
ESEbubekir Senates
Ebubekir Senates
YYYusuf Yilmaz
Yusuf Yilmaz
CUCelal Ulasoglu
Celal Ulasoglu
ITIlyas Tuncer
Ilyas Tuncer
AIM: To analyze the relationship between the serum lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) levels and clinical and histopathological features of biopsy-confirmed nonalcoholic fatty liver disease (NAFLD) patients. METHODS: Fifty-three consecutive, biopsy-proven NAFLD patients (31 males and 22 females, mean age 42.5 ± 9.6 years) and 26 age- and gender-matched, healthy controls (14 males and 12 females, mean age 39 ± 10.7 years) were included. The patients with NAFLD were consecutive patients who had been admitted to the hepatology outpatient clinic within the last year and had been diagnosed with NAFLD as the result of liver biopsy. The healthy controls were individuals who attended the outpatient clinic for routine health control and had no known chronic illnesses. The histological evaluation was conducted according to the NAFLD activity scoring system recommended by The National Institute of Diabetes and Digestive and Kidney Diseases Nonalcoholic Steatohepatitis Clinical Research Network. The serum LOX-1 levels were measured using an ELISA kit (Life Science Inc. USCN. Wuhan, Catalog No. E1859Hu) in both patients and healthy controls. A receiver operating characteristic (ROC) curve analysis was used to identify the optimal cutoff value of LOX-1 and thereby distinguish between patients with nonalcoholic steatohepatitis (NASH) and healthy controls. A P-value < 0.05 was considered statistically significant. RESULTS: NAFLD and healthy control groups were similar in terms of age and sex. NAFLD patients consisted of 8 patients with simple steatosis (15%), 27 with borderline NASH (51%) and 18 with definitive NASH (34%). Metabolic syndrome was found in 62.2% of the patients with NAFLD. The mean serum LOX-1 level in biopsy-proven NAFLD patients was 8.49 ± 6.43 ng/mL compared to 4.08 ± 4.32 ng/mL in healthy controls (P = 0.001). The LOX-1 levels were significantly different between controls, simple steatosis and NASH (borderline+definite) cases (4.08 ± 4.32 ng/mL, 6.1 ± 6.16 ng/mL, 8.92 ± 6.45 ng/mL, respectively, P = 0.004). When the cut-off value for the serum LOX-1 level was set at 5.35 ng/mL, and a ROC curve analysis was performed to distinguish between steatohepatitis patients and controls; the sensitivity and specificity of the serum LOX-1 level were 69.8% and 69.2%, respectively. CONCLUSION: The serum LOX-1 levels were significantly higher in NAFLD patients than in healthy controls. Additionally, the serum LOX-1 levels could differentiate between steatohepatitis patients and healthy controls.

1 January 2016 in Northern Clinics of Istanbul
Verified
Journal Article
Open access
OOOguzhan Ozturk
Oguzhan Ozturk
In patients with esophageal varices, P/S was found to be correlated with large varices with 82% sensitivity. However, this ratio did not predict large varices in patients with gastric varices. Prospective and randomized clinical researches are needed to clarify our findings.

1 June 2011
Verified
Closed access
YCYasar Colak
Yasar Colak
ITIlyas Tuncer
Ilyas Tuncer
FEFeruze Y Enc
Feruze Y Enc
OOOguzhan Ozturk
Oguzhan Ozturk
SKSafak Kiziltas
Safak Kiziltas
CUCelal Ulasoglu
Celal Ulasoglu